The Insulin Market in North America is expanding as healthcare systems, pharmaceutical manufacturers, and research institutions strengthen their focus on comprehensive diabetes care.

Market Overview

The insulin market is expected to grow to US$ 1,11,213.73 million by 2028 from US$ 60,183.09 million in 2022; the insulin market is estimated to grow with a CAGR of 10.8% from 2022-2028.  It is primarily prescribed for individuals with Type 1 diabetes and is also widely used by people with Type 2 diabetes when other treatment approaches are insufficient. Different insulin formulations are available to meet patients' varying treatment requirements, including rapid-acting, short-acting, intermediate-acting, long-acting, and premixed insulin.

Download Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00004051

Rising Prevalence of Diabetes

The growing prevalence of diabetes worldwide is a major factor supporting demand for insulin products. Lifestyle changes, sedentary behavior, obesity, dietary habits, and aging populations contribute to the increasing burden of Type 2 diabetes. People with Type 1 diabetes require ongoing insulin therapy, while many individuals with Type 2 diabetes eventually need insulin to maintain adequate glucose control. This growing patient population is encouraging pharmaceutical companies to strengthen insulin production and expand treatment availability.

Market Growth Drivers

Increasing awareness of diabetes management and the importance of maintaining stable blood glucose levels is supporting the adoption of insulin therapies. Healthcare providers are emphasizing early diagnosis, regular glucose monitoring, and personalized treatment plans to reduce the risk of diabetes-related complications. Improved access to healthcare services, expansion of diabetes care programs, and growing availability of insulin delivery products are further contributing to industry development.

Advancements in Insulin Formulations

Pharmaceutical innovation is influencing the development of modern insulin products. Manufacturers are focusing on improving insulin formulations to support more convenient administration, predictable glucose control, and patient adherence. Long-acting and rapid-acting insulin products provide different treatment options based on individual requirements. Continued research into insulin analogs and combination therapies is also supporting improvements in diabetes care.

Insulin Market Growth 

Advancements in insulin delivery systems are creating opportunities across the industry. Insulin pens, pumps, and automated insulin delivery technologies are helping patients manage their treatment more conveniently. Smart insulin pens and connected devices can support dose tracking and improve communication between patients and healthcare professionals. Increasing adoption of continuous glucose monitoring systems alongside insulin delivery technologies is also supporting more coordinated diabetes management.

Growing Adoption of Biosimilar Insulin

Biosimilar insulin products are gaining attention as healthcare systems seek additional treatment options and improved affordability. These products can contribute to broader access to insulin therapy, depending on regulatory approval, clinical suitability, and healthcare coverage. Pharmaceutical companies are investing in biosimilar development and manufacturing capabilities to strengthen their presence in the diabetes treatment landscape.

Increasing Focus on Patient-Centered Diabetes Care

Healthcare providers are increasingly emphasizing individualized diabetes management based on patients' glucose levels, lifestyle, treatment preferences, and medical needs. Education programs and digital health platforms are helping patients understand insulin administration, glucose monitoring, and treatment adherence. Greater awareness of diabetes complications is also encouraging patients to seek consistent medical guidance and follow appropriate insulin regimens.

Key Players

• Eli Lily and Company

• Novo NordiskA/S

• Biocon

• Wockhardt

• Adocia

• GlaxoSmitheKline plc

• Sanofi

• Pfizer

• Merck &Co., Inc.

• Tonghua Dongbao Pharmaceutical Co., Ltd.

• Bigfoot Biomedical, Inc.

Regional Growth Opportunities

The adoption of insulin products varies across regions according to diabetes prevalence, healthcare infrastructure, treatment affordability, and access to medicines. Developed healthcare systems benefit from established diabetes management services and wider availability of advanced insulin delivery technologies. Meanwhile, emerging economies are strengthening diabetes awareness programs, healthcare infrastructure, and pharmaceutical distribution networks to improve access to insulin therapy.

Future Outlook

The insulin industry is expected to remain an essential part of diabetes care as the global burden of diabetes continues to increase. Advancements in insulin formulations, connected delivery devices, biosimilar development, and personalized treatmen

Related Reports

Hormonal Contraceptive Market Share, Growth & Demand by 2034

Hospital Air Purifiers Market Demand, Trends & Forecast by 2034

About Us

The Insight Partners provides comprehensive syndicated and tailored market research services in the healthcare, technology, and industrial domains. Renowned for delivering strategic intelligence and practical insights, the firm empowers businesses to remain competitive in ever-evolving global markets.

Contact Us

Contact Person: Ankit Mathur
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876

Also Available in : Korean German Japanese French Chinese Italian Spanish